Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Hemay005 in Healthy Volunteers
NCT03577626Phase 1Unknown
- Sponsor
- Tianjin Hemay Biotech
- Start
- Oct 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of mufemilast in psoriasis (2 arms), sponsored by Tianjin Hemay Biotech. Primary endpoints: Maximum Plasma Concentration at 72 hours, Time to Maximum Plasma Concentration at 72 hours and 4 more. Status: unknown.
02
Drugs
mufemilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03577626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03577626.